{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T15:19:49Z","timestamp":1781277589176,"version":"3.54.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["T-32 CA009592"],"award-info":[{"award-number":["T-32 CA009592"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["RSG-21-151-01-CDP"],"award-info":[{"award-number":["RSG-21-151-01-CDP"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001513","name":"Breast Cancer Alliance","doi-asserted-by":"publisher","award":["none"],"award-info":[{"award-number":["none"]}],"id":[{"id":"10.13039\/100001513","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Triple-negative breast cancer is associated with poor patient prognosis and high rates of distant metastasis. These patients are at elevated risk of brain metastasis, which remains a major therapeutic challenge. IL13RA2, a high-affinity receptor for IL13, is highly expressed in primary brain cancers, many extracranial solid tumors, and in lung- and brain-seeking metastatic variant cell lines. However, the relationship between IL13RA2 and patient prognosis is variable, and the biological function of this receptor in cancer remains controversial. We sought to define the role of IL13RA2 in triple-negative breast cancer growth and metastasis, with an emphasis on breast-to-brain metastasis. We generated IL13RA2-CRISPR knockout derivatives of the human brain-seeking breast cancer cell line MDA231BrM2, as well as murine 4T1 cells, and evaluated changes in gene expression, proliferation, survival, and metastatic growth in vivo. Both IL13RA2-deficient models demonstrate enhanced cell survival in vitro, as well as augmented metastatic tumor growth and worsened animal survival in intracardiac models of brain metastasis. Concordantly, elevated <jats:italic>IL13RA2<\/jats:italic> mRNA expression is positively correlated with overall survival in patients with basal-like breast cancer. Mechanistically, IL13RA2-deficient cells exhibit increased AKT and NF-\u03baB signaling. These cells are sensitive to inhibition of either pathway, but especially AKT, which may represent a clinically useful vulnerability for patients with IL13RA2-low tumors. Our data suggest that inhibition of IL13RA2, though promising in other tumor contexts, may be deleterious in metastatic triple-negative breast cancer.<\/jats:p>","DOI":"10.1007\/s10585-025-10362-1","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T04:18:50Z","timestamp":1752553130000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Loss of IL13RA2 promotes metastatic tumor growth in triple-negative breast cancer via increased AKT and NF-\u03baB signaling"],"prefix":"10.1007","volume":"42","author":[{"given":"Wendy E.","family":"Bindeman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C.","family":"Corn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjan","family":"Rafat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1132-0782","authenticated-orcid":false,"given":"Barbara","family":"Fingleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"10362_CR1","unstructured":"Cancer Stat Facts: Female Breast Cancer Subtypes (SEER 22 2017\u20132021) National Cancer institute. https:\/\/www.seer.cancer.gov. Accessed 5 December 2024"},{"key":"10362_CR2","unstructured":"Triple Negative Breast Cancer (2021) PathologyOutlines.com. https:\/\/www.pathologyoutlines.com\/topic\/breastmalignanttripleneg.html. Accessed 15 February 2025"},{"issue":"5","key":"10362_CR3","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1200\/jop.2017.023333","volume":"13","author":"RLB Costa","year":"2017","unstructured":"Costa RLB, Gradishar WJ (2017) Triple-negative breast cancer: current practice and future directions. J Oncol Pract 13(5):301\u2013303. https:\/\/doi.org\/10.1200\/jop.2017.023333","journal-title":"J Oncol Pract"},{"issue":"12","key":"10362_CR4","doi-asserted-by":"publisher","first-page":"e924","DOI":"10.7759\/cureus.924","volume":"8","author":"X Wu","year":"2016","unstructured":"Wu X, Baig A, Kasymjanova G, Kafi K, Holcroft C, Mekouar H et al (2016) Pattern of local recurrence and distant metastasis in breast cancer by molecular subtype. Cureus 8(12):e924. https:\/\/doi.org\/10.7759\/cureus.924","journal-title":"Cureus"},{"key":"10362_CR5","doi-asserted-by":"crossref","unstructured":"Ostrom QT, Wright CH, Barnholtz-Sloan JS (2018) Chap. 2: brain metastases: epidemiology. In: Schiff D, Van den Bent MJ (eds) Handbook of clinical neurology. Elsevier, pp 27\u201342","DOI":"10.1016\/B978-0-12-811161-1.00002-5"},{"issue":"2","key":"10362_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.21037\/cco-21-90","volume":"11","author":"K Diao","year":"2021","unstructured":"Diao K, Sosa AJ, Zada G, Nagpal S, Chang EL (2021) Management of complications from brain metastasis treatment: a narrative review. Chin Clin Oncol 11(2):11. https:\/\/doi.org\/10.21037\/cco-21-90","journal-title":"Chin Clin Oncol"},{"key":"10362_CR7","doi-asserted-by":"publisher","unstructured":"Leone JP, Leone BA (2015) Breast cancer brain metastases: the last frontier. Exp Hematol Oncol 4(1). https:\/\/doi.org\/10.1186\/s40164-015-0028-8","DOI":"10.1186\/s40164-015-0028-8"},{"issue":"3","key":"10362_CR8","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.trecan.2018.01.003","volume":"4","author":"M Valiente","year":"2018","unstructured":"Valiente M, Ahluwalia MS, Boire A, Brastianos PK, Goldberg SB, Lee EQ et al (2018) The evolving landscape of brain metastasis. Trends Cancer 4(3):176\u2013196. https:\/\/doi.org\/10.1016\/j.trecan.2018.01.003","journal-title":"Trends Cancer"},{"issue":"8","key":"10362_CR9","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.clbc.2023.07.008","volume":"23","author":"R Bansal","year":"2023","unstructured":"Bansal R, Van Swearingen AED, Anders CK (2023) Triple negative breast cancer and brain metastases. Clin Breast Cancer 23(8):825\u2013831. https:\/\/doi.org\/10.1016\/j.clbc.2023.07.008","journal-title":"Clin Breast Cancer"},{"issue":"5","key":"10362_CR10","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41571-019-0320-3","volume":"17","author":"JH Suh","year":"2020","unstructured":"Suh JH, Kotecha R, Chao ST, Ahluwalia MS, Sahgal A, Chang EL (2020) Current approaches to the management of brain metastases. Nat Rev Clin Oncol 17(5):279\u2013299. https:\/\/doi.org\/10.1038\/s41571-019-0320-3","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10362_CR11","doi-asserted-by":"publisher","first-page":"E11","DOI":"10.3171\/foc.2006.20.4.6","volume":"20","author":"T Shimamura","year":"2006","unstructured":"Shimamura T, Husain SR, Puri RK (2006) The IL-4 and IL-13 pseudomonas exotoxins: new hope for brain tumor therapy. Neurosurg Focus 20(4):E11. https:\/\/doi.org\/10.3171\/foc.2006.20.4.6","journal-title":"Neurosurg Focus"},{"issue":"5","key":"10362_CR12","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1007\/BF03401786","volume":"6","author":"W Debinski","year":"2000","unstructured":"Debinski W, Gibo DM (2000) Molecular expression analysis of restrictive receptor for Interleukin 13, a brain tumor-associated cancer\/testis antigen. Mol Med 6(5):440\u2013449","journal-title":"Mol Med"},{"issue":"4","key":"10362_CR13","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1158\/1541-7786.mcr-17-0460","volume":"16","author":"H Deng","year":"2018","unstructured":"Deng H, Zeng J, Zhang T, Gong L, Zhang H, Cheung E et al (2018) Histone H3.3K27M mobilizes multiple cancer\/testis (CT) antigens in pediatric glioma. Mol Cancer Res 16(4):623\u2013633. https:\/\/doi.org\/10.1158\/1541-7786.mcr-17-0460","journal-title":"Mol Cancer Res"},{"issue":"7249","key":"10362_CR14","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/nature08021","volume":"459","author":"PD Bos","year":"2009","unstructured":"Bos PD, Zhang XHF, Nadal C, Shu W, Gomis RR, Nguyen DX et al (2009) Genes that mediate breast cancer metastasis to the brain. Nature 459(7249):1005\u20131009. https:\/\/doi.org\/10.1038\/nature08021","journal-title":"Nature"},{"issue":"7050","key":"10362_CR15","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/nature03799","volume":"436","author":"AJ Minn","year":"2005","unstructured":"Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD et al (2005) Genes that mediate breast cancer metastasis to lung. Nature 436(7050):518\u2013524. https:\/\/doi.org\/10.1038\/nature03799","journal-title":"Nature"},{"key":"10362_CR16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-0361","author":"RA M\u00e1rquez-Ortiz","year":"2021","unstructured":"M\u00e1rquez-Ortiz RA, Contreras-Zarate MJ, Tesic V, Alvarez-Eraso KL, Kwak G, Littrell Z et al (2021) IL13R\u03b12 promotes proliferation and outgrowth of breast cancer brain metastases. Clin Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.ccr-21-0361","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10362_CR17","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1038\/s41467-017-01392-9","volume":"8","author":"JP Newman","year":"2017","unstructured":"Newman JP, Wang GY, Arima K, Guan SP, Waters MR, Cavenee WK et al (2017) Interleukin-13 receptor alpha 2 cooperates with EGFRvIII signaling to promote glioblastoma multiforme. Nat Commun 8(1):1913. https:\/\/doi.org\/10.1038\/s41467-017-01392-9","journal-title":"Nat Commun"},{"issue":"11","key":"10362_CR18","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1158\/0008-5472.can-11-4090","volume":"72","author":"R Barderas","year":"2012","unstructured":"Barderas R, Bartolom\u00e9 RA, Fernandez-Ace\u00f1ero MJ, Torres S, Casal JI (2012) High expression of IL-13 receptor \u03b12 in colorectal cancer is associated with invasion, liver metastasis, and poor prognosis. Cancer Res 72(11):2780\u20132790. https:\/\/doi.org\/10.1158\/0008-5472.can-11-4090","journal-title":"Cancer Res"},{"issue":"12","key":"10362_CR19","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1158\/0008-5472.can-14-3650","volume":"75","author":"RA Bartolom\u00e9","year":"2015","unstructured":"Bartolom\u00e9 RA, Garc\u00eda-Palmero I, Torres S, L\u00f3pez-Lucendo M, Balyasnikova IV, Casal JI (2015) IL13 receptor \u03b12 signaling requires a scaffold protein, FAM120A, to activate the FAK and PI3K pathways in colon cancer metastasis. Cancer Res 75(12):2434\u20132444. https:\/\/doi.org\/10.1158\/0008-5472.can-14-3650","journal-title":"Cancer Res"},{"key":"10362_CR20","doi-asserted-by":"publisher","unstructured":"Bartolom\u00e9 RA, Mart\u00edn-Regalado \u00c1, Ja\u00e9n M, Zannikou M, Zhang P, de Los R\u00edos V et al (2020) Protein tyrosine Phosphatase-1B Inhibition disrupts IL13R\u03b12-promoted invasion and metastasis in cancer cells. Cancers (Basel) 12(2). https:\/\/doi.org\/10.3390\/cancers12020500","DOI":"10.3390\/cancers12020500"},{"issue":"11","key":"10362_CR21","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/s41419-023-06255-4","volume":"14","author":"RA Bartolom\u00e9","year":"2023","unstructured":"Bartolom\u00e9 RA, Mart\u00edn-Regalado \u00c1, Pintado-Berninches L, Robles J, Ram\u00edrez-Gonz\u00e1lez M\u00c1, Boukich I et al (2023) Schnurri-3 drives tumor growth and invasion in cancer cells expressing interleukin-13 receptor alpha 2. Cell Death Dis 14(11):742. https:\/\/doi.org\/10.1038\/s41419-023-06255-4","journal-title":"Cell Death Dis"},{"issue":"1","key":"10362_CR22","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13058-015-0607-y","volume":"17","author":"P Papageorgis","year":"2015","unstructured":"Papageorgis P, Ozturk S, Lambert AW, Neophytou CM, Tzatsos A, Wong CK et al (2015) Targeting IL13Ralpha2 activates STAT6-TP63 pathway to suppress breast cancer lung metastasis. Breast Cancer Res 17(1):98. https:\/\/doi.org\/10.1186\/s13058-015-0607-y","journal-title":"Breast Cancer Res"},{"key":"10362_CR23","doi-asserted-by":"publisher","unstructured":"Li X, Xiao X, Wang Y, Gu G, Li T, Wang Y et al (2024) Expression of Interleukin-13 receptor alpha 2 in brainstem gliomas. Cancers (Basel) 16(1). https:\/\/doi.org\/10.3390\/cancers16010228","DOI":"10.3390\/cancers16010228"},{"issue":"2","key":"10362_CR24","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/2211-5463.12774","volume":"10","author":"M Wang","year":"2020","unstructured":"Wang M, Yao R, Wang Y (2020) Silencing of IL13RA2 promotes partial epithelial-mesenchymal transition in hepatocellular carcinoma via ERK signaling pathway activation. FEBS Open Bio 10(2):229\u2013236. https:\/\/doi.org\/10.1002\/2211-5463.12774","journal-title":"FEBS Open Bio"},{"issue":"3","key":"10362_CR25","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s11060-022-04196-0","volume":"160","author":"V Khristov","year":"2022","unstructured":"Khristov V, Nesterova D, Trifoi M, Clegg T, Daya A, Barrett T et al (2022) Plasma IL13R\u03b12 as a novel liquid biopsy biomarker for glioblastoma. J Neuro-Oncol 160(3):743\u2013752. https:\/\/doi.org\/10.1007\/s11060-022-04196-0","journal-title":"J Neuro-Oncol"},{"issue":"1","key":"10362_CR26","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1186\/s12967-024-05413-2","volume":"22","author":"M Talia","year":"2024","unstructured":"Talia M, Cesario E, Cirillo F, Scordamaglia D, Di Dio M, Zicarelli A et al (2024) Cancer-associated fibroblasts (CAFs) gene signatures predict outcomes in breast and prostate tumor patients. J Transl Med 22(1):597. https:\/\/doi.org\/10.1186\/s12967-024-05413-2","journal-title":"J Transl Med"},{"issue":"12","key":"10362_CR27","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1084\/jem.194.12.1743","volume":"194","author":"K Kawakami","year":"2001","unstructured":"Kawakami K, Kawakami M, Snoy PJ, Husain SR, Puri RK (2001) In vivo overexpression of IL-13 receptor alpha2 chain inhibits tumorigenicity of human breast and pancreatic tumors in immunodeficient mice. J Exp Med 194(12):1743\u20131754. https:\/\/doi.org\/10.1084\/jem.194.12.1743","journal-title":"J Exp Med"},{"issue":"28","key":"10362_CR28","doi-asserted-by":"publisher","first-page":"16921","DOI":"10.1074\/jbc.271.28.16921","volume":"271","author":"D Caput","year":"1996","unstructured":"Caput D, Laurent P, Kaghad M, Lelias JM, Lefort S, Vita N et al (1996) Cloning and characterization of a specific Interleukin (IL)-13 binding protein structurally related to the IL-5 receptor alpha chain. J Biol Chem 271(28):16921\u201316926. https:\/\/doi.org\/10.1074\/jbc.271.28.16921","journal-title":"J Biol Chem"},{"issue":"5","key":"10362_CR29","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.4049\/jimmunol.161.5.2317","volume":"161","author":"DD Donaldson","year":"1998","unstructured":"Donaldson DD, Whitters MJ, Fitz LJ, Neben TY, Finnerty H, Henderson SL et al (1998) The murine IL-13 receptor alpha 2: molecular cloning, characterization, and comparison with murine IL-13 receptor alpha 1. J Immunol 161(5):2317\u20132324","journal-title":"J Immunol"},{"issue":"8","key":"10362_CR30","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s10585-015-9747-9","volume":"32","author":"KV Bankaitis","year":"2015","unstructured":"Bankaitis KV, Fingleton B (2015) Targeting IL4\/IL4R for the treatment of epithelial cancer metastasis. Clin Exp Metastasis 32(8):847\u2013856. https:\/\/doi.org\/10.1007\/s10585-015-9747-9","journal-title":"Clin Exp Metastasis"},{"issue":"16","key":"10362_CR31","doi-asserted-by":"publisher","first-page":"4329","DOI":"10.1158\/0008-5472.can-14-0093","volume":"74","author":"KT Venmar","year":"2014","unstructured":"Venmar KT, Carter KJ, Hwang DG, Dozier EA, Fingleton B (2014) IL4 receptor ILR4alpha regulates metastatic colonization by mammary tumors through multiple signaling pathways. Cancer Res 74(16):4329\u20134340. https:\/\/doi.org\/10.1158\/0008-5472.can-14-0093","journal-title":"Cancer Res"},{"issue":"5","key":"10362_CR32","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.bbamcr.2015.02.020","volume":"1853","author":"KT Venmar","year":"2015","unstructured":"Venmar KT, Kimmel DW, Cliffel DE, Fingleton B (2015) IL4 receptor alpha mediates enhanced glucose and glutamine metabolism to support breast cancer growth. Biochim Biophys Acta 1853(5):1219\u20131228. https:\/\/doi.org\/10.1016\/j.bbamcr.2015.02.020","journal-title":"Biochim Biophys Acta"},{"key":"10362_CR33","doi-asserted-by":"publisher","unstructured":"Williams D, Hargrove-Wiley E, Bindeman W, Valent D, Miranda AX, Beckstead J et al (2024) Type II Interleukin-4 receptor activation in basal breast cancer cells promotes tumor progression via metabolic and epigenetic modulation. Int J Mol Sci 25(9). https:\/\/doi.org\/10.3390\/ijms25094647","DOI":"10.3390\/ijms25094647"},{"issue":"24","key":"10362_CR34","doi-asserted-by":"publisher","first-page":"6338","DOI":"10.1158\/0008-5472.can-12-3544","volume":"72","author":"MA Hallett","year":"2012","unstructured":"Hallett MA, Venmar KT, Fingleton B (2012) Cytokine stimulation of epithelial cancer cells: the similar and divergent functions of IL-4 and IL-13. Cancer Res 72(24):6338. https:\/\/doi.org\/10.1158\/0008-5472.can-12-3544","journal-title":"Cancer Res"},{"issue":"6","key":"10362_CR35","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1084\/jem.20020903","volume":"197","author":"MG Chiaramonte","year":"2003","unstructured":"Chiaramonte MG, Mentink-Kane M, Jacobson BA, Cheever AW, Whitters MJ, Goad MEP et al (2003) Regulation and function of the Interleukin 13 receptor \u03b1 2 during a T helper cell type 2\u2013dominant immune response. J Exp Med 197(6):687\u2013701. https:\/\/doi.org\/10.1084\/jem.20020903","journal-title":"J Exp Med"},{"issue":"1","key":"10362_CR36","doi-asserted-by":"publisher","first-page":"111","DOI":"10.4049\/jimmunol.1301761","volume":"193","author":"S Chandriani","year":"2014","unstructured":"Chandriani S, DePianto DJ, N\u2019Diaye EN, Abbas AR, Jackman J, Bevers J III, et al (2014) Endogenously expressed IL-13R\u03b12 attenuates IL-13-mediated responses but does not activate signaling in human lung fibroblasts. J Immunol 193(1):111\u2013119. https:\/\/doi.org\/10.4049\/jimmunol.1301761","journal-title":"J Immunol"},{"issue":"1","key":"10362_CR37","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nm1332","volume":"12","author":"S Fichtner-Feigl","year":"2006","unstructured":"Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A (2006) IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 12(1):99\u2013106. https:\/\/doi.org\/10.1038\/nm1332","journal-title":"Nat Med"},{"issue":"22","key":"10362_CR38","doi-asserted-by":"publisher","first-page":"8678","DOI":"10.1158\/0008-5472.can-09-2100","volume":"69","author":"T Fujisawa","year":"2009","unstructured":"Fujisawa T, Joshi B, Nakajima A, Puri RK (2009) A novel role of interleukin-13 receptor alpha2 in pancreatic cancer invasion and metastasis. Cancer Res 69(22):8678\u20138685. https:\/\/doi.org\/10.1158\/0008-5472.can-09-2100","journal-title":"Cancer Res"},{"issue":"2","key":"10362_CR39","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/ijc.26366","volume":"131","author":"T Fujisawa","year":"2012","unstructured":"Fujisawa T, Joshi BH, Puri RK (2012) IL-13 regulates cancer invasion and metastasis through IL-13R\u03b12 via ERK\/AP-1 pathway in mouse model of human ovarian cancer. Int J Cancer 131(2):344\u2013356. https:\/\/doi.org\/10.1002\/ijc.26366","journal-title":"Int J Cancer"},{"issue":"2","key":"10362_CR40","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1158\/1078-0432.ccr-09-2015","volume":"16","author":"T Shimamura","year":"2010","unstructured":"Shimamura T, Fujisawa T, Husain SR, Joshi B, Puri RK (2010) Interleukin 13 mediates signal transduction through Interleukin 13 receptor alpha2 in pancreatic ductal adenocarcinoma: role of IL-13 Pseudomonas exotoxin in pancreatic cancer therapy. Clin Cancer Res 16(2):577\u2013586. https:\/\/doi.org\/10.1158\/1078-0432.ccr-09-2015","journal-title":"Clin Cancer Res"},{"key":"10362_CR41","doi-asserted-by":"publisher","first-page":"12752","DOI":"10.1038\/ncomms12752","volume":"7","author":"CM Lee","year":"2016","unstructured":"Lee CM, He CH, Nour AM, Zhou Y, Ma B, Park JW et al (2016) IL-13R\u03b12 uses TMEM219 in chitinase 3-like-1-induced signalling and effector responses. Nat Commun 7:12752. https:\/\/doi.org\/10.1038\/ncomms12752","journal-title":"Nat Commun"},{"issue":"4","key":"10362_CR42","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.celrep.2013.07.032","volume":"4","author":"CH He","year":"2013","unstructured":"He CH, Lee CG, Dela Cruz CS, Lee CM, Zhou Y, Ahangari F et al (2013) Chitinase 3-like 1 regulates cellular and tissue responses via IL-13 receptor \u03b12. Cell Rep 4(4):830\u2013841. https:\/\/doi.org\/10.1016\/j.celrep.2013.07.032","journal-title":"Cell Rep"},{"key":"10362_CR43","doi-asserted-by":"publisher","first-page":"878365","DOI":"10.3389\/fimmu.2022.878365","volume":"13","author":"KM Knudson","year":"2022","unstructured":"Knudson KM, Hwang S, McCann MS, Joshi BH, Husain SR, Puri RK (2022) Recent advances in IL-13R\u03b12-directed cancer immunotherapy. Front Immunol 13:878365. https:\/\/doi.org\/10.3389\/fimmu.2022.878365","journal-title":"Front Immunol"},{"issue":"36","key":"10362_CR44","doi-asserted-by":"publisher","first-page":"30215","DOI":"10.1074\/jbc.m112.370015","volume":"287","author":"IV Balyasnikova","year":"2012","unstructured":"Balyasnikova IV, Wainwright DA, Solomaha E, Lee G, Han Y, Thaci B et al (2012) Characterization and immunotherapeutic implications for a novel antibody targeting Interleukin (IL)-13 receptor \u03b12. J Biol Chem 287(36):30215\u201330227. https:\/\/doi.org\/10.1074\/jbc.m112.370015","journal-title":"J Biol Chem"},{"issue":"8","key":"10362_CR45","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/s41416-018-0259-7","volume":"119","author":"RA Bartolom\u00e9","year":"2018","unstructured":"Bartolom\u00e9 RA, Ja\u00e9n M, Casal JI (2018) An IL13R\u03b12 peptide exhibits therapeutic activity against metastatic colorectal cancer. Br J Cancer 119(8):940\u2013949. https:\/\/doi.org\/10.1038\/s41416-018-0259-7","journal-title":"Br J Cancer"},{"issue":"5","key":"10362_CR46","doi-asserted-by":"publisher","first-page":"188802","DOI":"10.1016\/j.bbcan.2022.188802","volume":"1877","author":"M Ja\u00e9n","year":"2022","unstructured":"Ja\u00e9n M, Mart\u00edn-Regalado \u00c1, Bartolom\u00e9 RA, Robles J, Casal JI (2022) Interleukin 13 receptor alpha 2 (IL13R\u03b12): expression, signaling pathways and therapeutic applications in cancer. Biochim Biophys Acta (BBA): Rev Cancer 1877(5):188802. https:\/\/doi.org\/10.1016\/j.bbcan.2022.188802","journal-title":"Biochim Biophys Acta (BBA): Rev Cancer"},{"issue":"7","key":"10362_CR47","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T et al (2012) Fiji: an open-source platform for biological-image analysis. Nat Methods 9(7):676\u2013682. https:\/\/doi.org\/10.1038\/nmeth.2019","journal-title":"Nat Methods"},{"issue":"2","key":"10362_CR48","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s10585-020-10025-3","volume":"37","author":"B Banan","year":"2020","unstructured":"Banan B, Beckstead JA, Dunavant LE, Sohn Y, Adcock JM, Nomura S et al (2020) Development of a novel murine model of lymphatic metastasis. Clin Exp Metastasis 37(2):247\u2013255. https:\/\/doi.org\/10.1007\/s10585-020-10025-3","journal-title":"Clin Exp Metastasis"},{"key":"10362_CR49","doi-asserted-by":"publisher","first-page":"4101","DOI":"10.1016\/j.csbj.2021.07.014","volume":"19","author":"B Gy\u0151rffy","year":"2021","unstructured":"Gy\u0151rffy B (2021) Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer. Comput Struct Biotechnol J 19:4101\u20134109. https:\/\/doi.org\/10.1016\/j.csbj.2021.07.014","journal-title":"Comput Struct Biotechnol J"},{"issue":"6","key":"10362_CR50","first-page":"1399","volume":"52","author":"CJ Aslakson","year":"1992","unstructured":"Aslakson CJ, Miller FR (1992) Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52(6):1399\u20131405","journal-title":"Cancer Res"},{"issue":"17","key":"10362_CR51","doi-asserted-by":"publisher","first-page":"6674","DOI":"10.1073\/pnas.1117412109","volume":"109","author":"S Serres","year":"2012","unstructured":"Serres S, Soto MS, Hamilton A, McAteer MA, Carbonell WS, Robson MD et al (2012) Molecular MRI enables early and sensitive detection of brain metastases. Proc Natl Acad Sci USA 109(17):6674\u20136679. https:\/\/doi.org\/10.1073\/pnas.1117412109","journal-title":"Proc Natl Acad Sci USA"},{"key":"10362_CR52","doi-asserted-by":"publisher","unstructured":"Marone G, Granata F, Pucino V, Pecoraro A, Heffler E, Loffredo S et al (2019) The intriguing role of Interleukin 13 in the pathophysiology of asthma. Front Pharmacol 10. https:\/\/doi.org\/10.3389\/fphar.2019.01387","DOI":"10.3389\/fphar.2019.01387"},{"issue":"11","key":"10362_CR53","first-page":"1253","volume":"1","author":"W Debinski","year":"1995","unstructured":"Debinski W, Obiri NI, Powers SK, Pastan I, Puri RK (1995) Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Clin Cancer Res 1(11):1253\u20131258","journal-title":"Clin Cancer Res"},{"key":"10362_CR54","unstructured":"ClinicalTrials.gov (2025) National Institutes of Health. https:\/\/clinicaltrials.gov\/. Accessed 11 April"},{"issue":"8","key":"10362_CR55","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/neuonc\/nop054","volume":"12","author":"S Kunwar","year":"2010","unstructured":"Kunwar S, Chang S, Westphal M, Vogelbaum M, Sampson J, Barnett G et al (2010) Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol 12(8):871\u2013881. https:\/\/doi.org\/10.1093\/neuonc\/nop054","journal-title":"Neuro Oncol"},{"key":"10362_CR56","doi-asserted-by":"publisher","unstructured":"Ja\u00e9n M, Bartolom\u00e9 RA, Aizpurua C, Martin-Regalado \u00c1, Imbaud JI, Casal JI (2021) Inhibition of liver metastasis in colorectal cancer by targeting IL-13\/IL13R\u03b12 binding site with specific monoclonal antibodies. Cancers (Basel) 13(7). https:\/\/doi.org\/10.3390\/cancers13071731","DOI":"10.3390\/cancers13071731"},{"issue":"10","key":"10362_CR57","doi-asserted-by":"publisher","first-page":"e77769","DOI":"10.1371\/journal.pone.0077769","volume":"8","author":"CE Brown","year":"2013","unstructured":"Brown CE, Warden CD, Starr R, Deng X, Badie B, Yuan Y-C et al (2013) Glioma IL13R\u03b12 is associated with mesenchymal signature gene expression and poor patient prognosis. PLoS ONE 8(10):e77769. https:\/\/doi.org\/10.1371\/journal.pone.0077769","journal-title":"PLoS ONE"},{"issue":"3","key":"10362_CR58","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s11060-017-2680-9","volume":"136","author":"J Han","year":"2018","unstructured":"Han J, Puri RK (2018) Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor \u03b11 and \u03b12 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme. J Neurooncol 136(3):463\u2013474. https:\/\/doi.org\/10.1007\/s11060-017-2680-9","journal-title":"J Neurooncol"},{"key":"10362_CR59","doi-asserted-by":"publisher","unstructured":"Chao H, Zheng L, Hsu P, He J, Wu R, Xu S et al (2023) IL-13RA2 downregulation in fibroblasts promotes keloid fibrosis via JAK\/STAT6 activation. JCI Insight 8(6). https:\/\/doi.org\/10.1172\/jci.insight.157091","DOI":"10.1172\/jci.insight.157091"},{"issue":"12","key":"10362_CR60","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1038\/onc.2014.53","volume":"34","author":"Z Zhao","year":"2015","unstructured":"Zhao Z, Wang L, Xu W (2015) IL-13R\u03b12 mediates PNR-induced migration and metastasis in ER\u03b1-negative breast cancer. Oncogene 34(12):1596\u20131607. https:\/\/doi.org\/10.1038\/onc.2014.53","journal-title":"Oncogene"},{"issue":"6","key":"10362_CR61","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.4049\/jimmunol.1701442","volume":"200","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, He CH, Yang DS, Nguyen T, Cao Y, Kamle S et al (2018) Galectin-3 interacts with the CHI3L1 axis and contributes to Hermansky\u2013Pudlak syndrome lung disease. J Immunol 200(6):2140\u20132153. https:\/\/doi.org\/10.4049\/jimmunol.1701442","journal-title":"J Immunol"},{"issue":"1","key":"10362_CR62","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.gendis.2023.01.027","volume":"11","author":"B He","year":"2024","unstructured":"He B, Liang J, Qin Q, Zhang Y, Shi S, Cao J et al (2024) IL-13\/IL-13RA2 signaling promotes colorectal cancer stem cell tumorigenesis by inducing ubiquitinated degradation of p53. Genes Dis 11(1):495\u2013508. https:\/\/doi.org\/10.1016\/j.gendis.2023.01.027","journal-title":"Genes Dis"},{"issue":"4","key":"10362_CR63","first-page":"1103","volume":"62","author":"SO Rahaman","year":"2002","unstructured":"Rahaman SO, Sharma P, Harbor PC, Aman MJ, Vogelbaum MA, Haque SJ (2002) IL-13R\u03b12, a decoy receptor for IL-13 acts as an inhibitor of IL-4-dependent signal transduction in glioblastoma cells. Cancer Res 62(4):1103\u20131109","journal-title":"Cancer Res"},{"issue":"12","key":"10362_CR64","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1039\/c3mb70298g","volume":"9","author":"A-L Andrews","year":"2013","unstructured":"Andrews A-L, Nordgren IK, Campbell-Harding G, Holloway JW, Holgate ST, Davies DE et al (2013) The association of the cytoplasmic domains of Interleukin 4 receptor alpha and Interleukin 13 receptor alpha 2 regulates Interleukin 4 signaling. Mol Biosyst 9(12):3009\u20133014. https:\/\/doi.org\/10.1039\/c3mb70298g","journal-title":"Mol Biosyst"}],"container-title":["Clinical &amp; Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-025-10362-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10585-025-10362-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-025-10362-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T05:16:04Z","timestamp":1760073364000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10585-025-10362-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":64,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["10362"],"URL":"https:\/\/doi.org\/10.1007\/s10585-025-10362-1","relation":{},"ISSN":["1573-7276"],"issn-type":[{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"assertion":[{"value":"23 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal studies were approved by Vanderbilt\u2019s Institutional Animal Care and Use Committee (protocol M2300038-00).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Barbara Fingleton is a member of the editorial board for Clinical and Experimental Metastasis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}